Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07199894 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNE

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 30, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to compare combination of Solifenacin and MIrabegron in treatment of primary mono-symptomatic nocturnal enuresis in children. It will also learn about the safety of that combination. The main questions it aims to answer are: Does combination of Solifenacin and MIrabegron lower the number of wet nights? What medical problems do participants have when taking combination of Solifenacin and MIrabegron? Researchers will compare the combination to omegapress to see if the combination works better to treat primary mono-symptomatic nocturnal enuresis. Participants will: Take the combination or Omegapress every day for 3 months Visit the clinic once monthly for checkups and tests Keep a diary of their symptoms and the number of wet nights
Trial Details
NCT Number NCT07199894
Lead Sponsor Mansoura University
Conditions Nocturnal Enuresis in Children
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov